¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ HDKbF/  
*H122njH+T  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© _U0f=m  
M;NX:mX9  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© C?Ucu]cW  
nm+s{  
1.Co-stimulators (or co-stimulating molecules) .2pK.$.  
oE~RyS X  
2.NK-kB \1`O_DF~o  
@6d[=!9  
3.Immunoglobulin superfamily H[UlY?&+  
RyNs6  
4.antigen-presenting cell (APC) DJ%PWlK5  
&?vgP!d&M  
5.death domain 6Iw\c  
 9 a kH  
6.CCR and CXCR {|\.i  
KF/-wZ" 1s  
7.Lectin (or mitogen) +O5hH8<&b  
Wvqhl 'J  
8.Clusters of differentiation, CD) b[7 ]F  
rs.M]8a2{&  
9.B7 family \Roz$t-R|f  
MfQ!6zE  
10.Cytotoxic T lymphocyte, CTL) ipI LG4  
 }75e:w[  
11.IL-15 and IL-15 receptor (IL-15R) 2"5v[,$1H  
-^57oU  
12.MHC restriction  bF(f*u  
2m[<]$  
13.Affinity-chromatography m`_ONm'T&  
:@)>r9N  
14.Cyctosprin A, CsA ]7mt[2 Cd  
_y>~ yZx  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) _y3Xb`0a  
Z<4AL\l 98  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© f9\X>zzB2|  
\15nS B  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 RGU\h[  
4H-'Dr=G  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ QwJyY{O`  
9E 6R0D}  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ h*Pc=/p  
uH-)y,2&  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© h=%_Ao<x  
+'@Dz9:>  
ÃâÒßѧרҵ£º !3v1bGk  
xjUtl  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ +H2-ZXr  
XGMiW0j0B  
Ïû»¯ÄÚ¿Æ£º %!L9)(}"  
nJLFfXWx  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ \B 7tX  
_Y[bMuUb=  
ѪҺ²¡Ñ§×¨Òµ£º Yir [!{  
C{b gkzr  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»